March 1, 2017 / 12:09 PM / 7 months ago

BRIEF-Acceleron Q4 loss per share $0.51

March 1 (Reuters) - Acceleron Pharma Inc:

* Acceleron reports fourth quarter and year ended 2016 operational and financial results

* Acceleron Pharma Inc says outlined plans to initiate several new clinical trials in 2017

* Acceleron Pharma Inc says luspatercept phase 3 trials to complete enrollment in both MDS and beta-thalassemia trials in 2H 2017

* Qtrly loss per share $0.51

* Qtrly collaboration revenue $3.4 million versus $3.8 million Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below